Next Article in Journal
Optimized Anti-pathogenic Agents Based on Core/Shell Nanostructures and 2-((4-Ethylphenoxy)ethyl)-N-(substituted-phenylcarbamothioyl)-benzamides
Previous Article in Journal
The Complexities of Epidemiology and Prevention of Gastrointestinal Cancers
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2012, 13(10), 12573-12583; doi:10.3390/ijms131012573

Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) Inhibition of Human Osteosarcoma Angiogenesis via VEGF/PI3K/AKT Signaling

1
Department of Orthopaedics, The Affiliated Southeast Hospital of Xiamen University, Zhangzhou 363000, China
2
Department of Neurology, The Affiliated Southeast Hospital of Xiamen University, Zhangzhou 363000, China
3
Department of Thoracic Surgery, The Affiliated Tangdu Hospital of Fourth Military Medical University, Xi’an 710038, China
4
Department of Orthopaedics, The Affiliated Tangdu Hospital of Fourth Military Medical University, Xi’an 710038, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 13 August 2012 / Revised: 6 September 2012 / Accepted: 21 September 2012 / Published: 1 October 2012
(This article belongs to the Section Biochemistry, Molecular Biology and Biophysics)
View Full-Text   |   Download PDF [1232 KB, uploaded 19 June 2014]   |  

Abstract

Ether à go-go 1 (Eag1) channel is overexpressed in a variety of cancers but the therapeutic potential of Eag1 in osteosarcoma remains elusive. In this study, we constructed an Ad5-Eag1-shRNA vector and evaluated its efficiency for Eag1 knockdown and its effects on osteosarcoma. Our results showed that Ad5-Eag1-shRNA had high interference efficiency of Eag1 expression and suppressed osteosarcoma growth both in vitro and in vivo. To explore the molecular mechanism underlying tumor growth inhibition induced by Eag1 silencing, the intratumoral microvessel density (MVD) was assessed by CD31 staining and the expression of vascular endothelial growth factor (VEGF) was detected by Western blot analysis. We found that Eag1 silencing led to decreased angiogenesis and VEGF expression in the xenograft model of osteosarcoma. Finally, we detected a time-dependent decrease in VEGF expression and considerably reduced phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) activation in osteosarcoma cells treated by Eag1 shRNA. Taken together, our results suggest that Eag1 silencing inhibits tumor growth and angiogenesis in osteosarcoma via the down regulation of VEGF/PI3K/AKT signaling.
Keywords: Ether à go-go1 (Eag1); vascular endothelial growth factor (VEGF); proliferation; angiogenesis; short hairpin RNA(shRNA); osteosarcoma Ether à go-go1 (Eag1); vascular endothelial growth factor (VEGF); proliferation; angiogenesis; short hairpin RNA(shRNA); osteosarcoma
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Wu, J.; Wu, X.; Zhong, D.; Zhai, W.; Ding, Z.; Zhou, Y. Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) Inhibition of Human Osteosarcoma Angiogenesis via VEGF/PI3K/AKT Signaling. Int. J. Mol. Sci. 2012, 13, 12573-12583.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top